RE: Review26 Oct 2017 20:53
You're absolutely spot on with your assessment of Hikma. The SP is practically the same as the asset value of the Company. If anyone was to start a Pharmaceutical company and aim for exactly the same infrastructure that Hikma has at the moment they would find it impossible to do so for less than £5Billion and it would also take many, many years to achieve. Imagine the work that needs to be done in developing goodwill with suppliers, distributors, trading partners and end users. Locating and building distribution /Research centres, developing new drugs, finding the best Chemists and research Scientists etc etc. For this reason i believe the bottom has now been reached and the Shorters are really just squeezing the pips now.